Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Gross Margin (2016 - 2025)

Integra Lifesciences Holdings' Gross Margin history spans 17 years, with the latest figure at 50.78% for Q4 2025.

  • For Q4 2025, Gross Margin fell 549.0% year-over-year to 50.78%; the TTM value through Dec 2025 reached 50.86%, down 391.0%, while the annual FY2025 figure was 50.86%, 391.0% down from the prior year.
  • Gross Margin for Q4 2025 was 50.78% at Integra Lifesciences Holdings, down from 51.48% in the prior quarter.
  • Across five years, Gross Margin topped out at 62.83% in Q4 2022 and bottomed at 50.37% in Q2 2025.
  • The 5-year median for Gross Margin is 57.07% (2023), against an average of 57.3%.
  • The largest annual shift saw Gross Margin skyrocketed 265bps in 2022 before it crashed -840bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 61.47% in 2021, then grew by 2bps to 62.83% in 2022, then dropped by -9bps to 57.05% in 2023, then fell by -1bps to 56.27% in 2024, then fell by -10bps to 50.78% in 2025.
  • Per Business Quant, the three most recent readings for IART's Gross Margin are 50.78% (Q4 2025), 51.48% (Q3 2025), and 50.37% (Q2 2025).